Signal Expanded Access Case Report of SNIPR001 CRISPR Phage Therapy Published

Summary

Copenhagen-based SNIPR Biome announced on August 12, 2026 the publication of a peer-reviewed expanded-access case report in Clinical Infectious Diseases describing use of its CRISPR-armed phage therapeutic SNIPR001 in a kidney transplant recipient with drug-resistant, intracellular E. coli malakoplakia. The therapy, originally designed to act in the gut, was administered intravenously, topically and directly into lesions, marking the first documented use of SNIPR001 outside its original gut-targeted application. Within one week the patient's abdominal skin lesions began healing, with several fully healed by four weeks, while the intra-abdominal mass shrank from 744.6 cubic centimeters at baseline to 373.4 at eight weeks and to 82 cubic centimeters (an 89% reduction) after one year. The treatment was delivered by infectious disease investigators at UC San Diego under a single-patient emergency investigational new drug application. A separate Phase 1b/2a trial (NCT06938867) across eight U.S. centers, for which enrollment is complete, is evaluating oral SNIPR001 in 24 hematological cancer patients, and the therapy holds FDA Fast Track designation. CRISPR Medicine News cautioned that a single expanded-access case cannot establish causation for the clinical improvement.